In our previous studies with PBMC samples from a total 42 patients with malignant glioma [19], stimulation with the IL-13Rα 2 345–353:1a9V peptide induced antigen-specific CTL responses in 18 of 42 (42.9%) cases. This evidence concerns the gene IL13RA1 and malignant glioma.